Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITDAEPS (Basic)EPS (Weighted Average and Diluted)Income towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Summit Therapeutics (SMMT) Other Operating Expenses (2022 - 2024)

Summit Therapeutics' Other Operating Expenses history spans 3 years, with the latest figure at $205000.0 for Q4 2024.

  • For Q4 2024, Other Operating Expenses rose 14.53% year-over-year to $205000.0; the TTM value through Sep 2025 reached $205000.0, down 28.57%, while the annual FY2024 figure was $313000.0, 68.73% down from the prior year.
  • Other Operating Expenses reached $205000.0 in Q4 2024 per SMMT's latest filing, up from -$264000.0 in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $5.5 million in Q3 2022 to a low of -$264000.0 in Q3 2024.
  • Average Other Operating Expenses over 3 years is $790900.0, with a median of $209000.0 recorded in 2024.
  • The largest YoY upside for Other Operating Expenses was 688.89% in 2024 against a maximum downside of 199.62% in 2024.
  • A 3-year view of Other Operating Expenses shows it stood at $1.1 million in 2022, then plummeted by 84.2% to $179000.0 in 2023, then rose by 14.53% to $205000.0 in 2024.
  • Per Business Quant, the three most recent readings for SMMT's Other Operating Expenses are $205000.0 (Q4 2024), -$264000.0 (Q3 2024), and $159000.0 (Q2 2024).